Scientists have developed a new blood test that uses nanotechnology and electrical signals to detect pancreatic cancer with high accuracy.
Led by Stuart Ibsen, the test uses a microchip that applies a small electric charge to blood samples to capture tumor-derived nanoparticles. These particles are then labeled to identify cancer-specific biomarkers.
In a blinded study, the test achieved 97% accuracy in distinguishing pancreatic cancer from non-cancer conditions such as pancreatitis, outperforming traditional biopsy methods. It can also help differentiate malignant tumors from benign or precancerous lesions, which is difficult with current imaging techniques.
Because it only requires a blood draw, the test could enable earlier detection of pancreatic cancer, which is often diagnosed late due to deep tumor location and lack of early symptoms. Researchers say it may also reduce unnecessary surgeries and improve screening for high-risk individuals. The technology is still in development and is expected to take about five years before clinical use.